Product Code: RP-ID-10325475 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10325475
Market Overview:
Preimplantation Genetics Diagnosis (PGD) Market (By Test Type: Gender Selection, Chromosomal Abnormalities, Single Gene Disorders, HLA Typing, Aneuploidy, And Others; By Geography) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024
Global Preimplantation Genetics Diagnosis (PGD) Market is estimated to reach $140 Million by 2024; growing at a CAGR of 6.2% from 2016 to 2024. Preimplantation genetic diagnosis is a procedure which involves genetic profiling of embryos, so as to reduce the possibility of passing on inherited disorders. It aids in detecting embryos with abnormalities and selects healthy embryo that can be used for implanting in the uterus. It decreases the rate of unprompted abortion and increased the probabilities of delivering genetically healthy baby. It majorly helps couples whose offspring are capable of getting affected by severe mendelian disorders, mitochondrial disorders or structural chromosome abnormalities. Presently, PGD is the only available technique which are used to avoid highly affected embryo before implantation.
The factors driving the global preimplantation genetics diagnosis (PGD) market includes decreasing fertility rate, technological advancements in the field of genetic analysis, rising demand for IVF treatments, increasing commonness of genetic disorders, and risk of affecting genetic disorders in embryos with increasing maternal age. Though, ethical and economic concerns and several government regulations would hinder the growth of the market. Furthermore, technological advancements and untapped markets would provide numerous growth opportunities in the forecast period.
The global preimplantation genetics diagnosis (PGD) is segmented on the basis of test type and geography. Test type is further bifurcated as X-linked diseases, HLA typing, chromosomal abnormalities, gender selection, single gene disorders, aneuploidy, and other test types.
Based on geography, global market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is further bifurcated in U.S., Canada, and Mexico whereas Europe consist of UK, Germany, France, and others. Asia-Pacific is segmented into India, China, Japan, and others, while RoW is bifurcated into South America, Middle East and Africa.
The key market players include Thermo Fisher Scientific, Inc., Cooper Surgical, Inc., Abbott Laboratories, Agilent Technologies, Inc., Natera, Inc., PerkinElmer, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., PerkinElmer, Inc., and Beijing Genomics Institute (BGI), among others.
The key takeaways from the report
The report will provide detailed analysis of Preimplantation Genetics Diagnosis (PGD) Market with respect to major segments such as test type, and geography
The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
An exhaustive regional analysis of Preimplantation Genetics Diagnosis (PGD) Market has been included in the report
Profile of the key players in the Preimplantation Genetics Diagnosis (PGD) Market will be provided, which include key financials, product & services, new developments and business strategies
Scope of Preimplantation Genetics Diagnosis (PGD) Market
Test Type Segments
X-Linked Diseases
HLA Typing
Chromosomal Abnormalities
Gender Selection
Single Gene Disorders
Aneuploidy
Other Test Types
Geographical Segments
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Others
Asia Pacific
India
China
Japan
Others
RoW
South America
Middle East
Africa
0
Related Reports
Proof of Quality & Reliability
